Director Greene John buys 7,000 shares of CRSP at $44.85 ($313.9K); stock -50.7% from 52-week high, company posts -90.0% revenue decline and $-85.9M loss.
Director John Greene purchased 7,000 shares of CRISPR Therapeutics at $44.85 per share on 2025-02-26, establishing a new position worth $313.9K. This occurs while the company is under severe operational stress: annual revenue contracted -90.0% to $602.0K in the latest quarter, the company posted a $-85.9M net loss over its most recent full fiscal year, and the stock trades -50.7% below its 52-week high of $89.12. Greene's own cross-ticker track record shows poor timing on prior sales (0.00% well-timed rate), indicating this purchase does not necessarily signal a bullish inflection. The combination of material share acquisition by a director alongside deeply depressed fundamentals and a director with a history of poorly timed exits suggests this transaction warrants investor scrutiny of the company's cash position, timeline to profitability, and forward guidance.